SUPN logo

SUPNSupernus Pharmaceuticals Inc

$44.41
$1.14
(2.50%)
Today
Closed $44.41
$0.00
(0.00%)
After Hours
Updated: 04:10 PM EDT
EarningsAug 4
Mkt Cap$2.58B
Vol825,357.00
News
all
press releases
Should You Buy, Sell or Hold BIIB Stock After it Rises Almost 12% YTD?
Biogen climbs 11.5% YTD as new drugs, pipeline progress and M&A activity fuel confidence in Biogen???s multiyear turnaround.
Zacks
News Placeholder
More News
News Placeholder
What to Know About This Fund's Sale of a Pharma Stock Up 56% in a Year
Key PointsQuantedge Capital exited 89,600 shares of Supernus Pharmaceuticals in the first quarter, with an estimated trade size of $4.56 million based on quarterly average prices...
Nasdaq News: Markets
News Placeholder
Supernus Pharmaceuticals Q1 Earnings Call Highlights
Supernus Pharmaceuticals (NASDAQ:SUPN) reported first-quarter 2026 results that management said reflected "a strong start to the year," driven by growth across its key brands and collaboration-related revenue. Chief Executive Officer Jack Khattar highlighted a 56% year-over-year increase in combined...
MarketBeat
News Placeholder
Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks
News Placeholder
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +110.71% and +10.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Quarterly Earnings Results
Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) issued its earnings results on Tuesday. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter...
MarketBeat
News Placeholder
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 5.0% during the fourth quarter, according to the company in its most recent Form...
MarketBeat
News Placeholder
Bausch Health (BHC) Lags Q1 Earnings Estimates
Bausch (BHC) delivered earnings and revenue surprises of -3.11% and +4.72%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs
Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.
Zacks
News Placeholder
Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Hold at Zacks Research
Zacks Research upgraded Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Monday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.